Prothena Corp Plc
Prothena Corp Plc (PRTA) Unusual Options Activity Today
PRTA options volume power reached 0.25x on the previous trading day. The highest reading was on the $11 CALL expiring 2027-01-15.
Read more
Checking PRTA unusual options activity helps you spot when traders are making outsized bets on Prothena Corp Plc before the broader market catches on. Prothena Corp Plc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor PRTA unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching PRTA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking PRTA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and PRTA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Catalysts rarely arrive without a footprint, and PRTA unusual options activity is often where that footprint shows up first. Our scanner tracks Prothena Corp Plc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at PRTA unusual options volume on the call side or chasing put sweeps, Prothena Corp Plc's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 1.00 | 5.30 | 9.50 | 7.40 | 604% | 0 | 0 | — |
| 2.00 | 4.30 | 8.50 | 6.40 | 400% | 0 | 0 | — |
| 3.00 | 3.40 | 7.50 | 5.45 | 321% | 0 | 0 | — |
| 4.00 | 3.50 | 5.50 | 4.50 | 260% | 0 | 0 | — |
| 5.00 | 1.50 | 4.50 | 3.00 | 26% | 0 | 0 | — |
| 1.00 | — | 0.05 | 0.05 | 510% | 0 | 0 | — |
| 2.00 | — | 0.95 | 0.95 | 888% | 0 | 0 | — |
| 3.00 | — | 1.75 | 1.75 | 937% | 0 | 0 | — |
| 4.00 | — | 1.00 | 1.00 | 493% | 0 | 0 | — |
| 5.00 | — | 0.75 | 0.75 | 328% | 0 | 0 | — |
As of September 25, 2026
Spot unusual options activity before it moves
Track PRTA options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→